

Compound 108 inhibits ATPase activity of Hsp90 protein
O.D. 620 nm
0.16
0.14
0.12
0.1
0.08
0.06
0.04
0.02
0
background
Geldanamycin (40uM)
Compound 108 (40uM)
Compound 108 (4uM)
Hsp90

Fig. 1



Her2
tubulin
untreated
5 uM
2 uM
0.5 uM
5 uM
2 uM
0.5 uM
5 uM
2 uM
0.5 uM
17AAG
108
49
© Synta Pharmaceuticals Corp. 2004

Fig. 2



Hsp90 inhibitors of the invention induce c-kit degradation in HEL92.1.7 cells
c-kit positive population (%)
100
90
80
70
60
50
40
30
20
10
0
isotype
untreated
17AAG (0.4uM)
Comp. 221 (0.4uM)
Comp. 221 (0.1uM)
Comp. 221 (0.05uM)
Comp. 226 (0.4uM)
Comp. 226 (0.1uM)

Fig. 3




Hsp90 inhibitors of the invention induce degradation of c-Kit in Kasumi-1 cells
% c-Kit positive cell
100
90
80
70
60
50
40
30
20
10
0
isotype control
untreated
17AAG (0.5uM)
Comp. 221 (0.5uM)
Comp. 221 (0.05uM)
Comp. 188 (0.5uM)
Comp. 188 (0.05uM)

Fig. 4


Hsp90 inhibitors induce degradation of c-Kit in Kasumi-1 cells



1: untreated
2: 17AAG (400nM)
3: 17AAG (100nM)
4: Comp. 221 (400nM)
5: Comp. 221 (100nM)

Fig. 5

C-Met Degradation induced by Hsp90 inhibitors in NCI-H1193 cells



1: Marker
2: Control (no treatment)
3: 17AAG (400 nM)
4: 17AAG 100 nM
5: Compound 221 (400 nM)
6: Compound 221 (100 nM)

Fig. 6



Vehicle
17-AAG (100 mg/kg)
Compound #49 (300 mg/kg)
Average Tumor Volume (mm3)
450.0
400.0
350.0
300.0
250.0
200.0
150.0
100.0
50.0
0.0
-7
-1
2
7
9
13
16
20
23
Days Relative to Start of Drug Treatment
(IP Dosing 5X/Week:)

Fig. 7



Vehicle
17-AAG (100 mg/kg)
Compound #49 (300 mg/kg)
Percent Change in Body Weight
10.0
8.0
6.0
4.0
2.0
0.0
-2.0
-4.0
1 2 3 6 7 8 9 10 11 13 14 15 16 17 20 21 23
Days Relative to Start of Drug Treatment
(IP Dosing 5X/Week:)

Fig. 8



Vehicle
17-AAG (75 mg/kg)
Compound #188 (200 mg/kg)
Average Tumor Volume (mm3)
2500.0
2000.0
1500.0
1000.0
500.0
0.0
16
19
22
25
28
31
34
37
Days Since Tumor Implantation
(I.p. Dosing 5X/Week:)

Fig. 9



Vehicle
17-AAG (75 mg/kg)
Compound #188 (200 mg/kg)
Percent Change In Body Weight
12.0
10.0
8.0
6.0
4.0
2.0
0.0
-2.0
17
20
23
26
29
32
35
38
Days Since Tumor Implantation
(I.p. Dosing 5X/Week:)

Fig. 10